关注 “环球资源外贸” 官方微信，获取实时外贸资讯
Product Information
Key Specifications/ Special Features
SM20, short for sg 20mg, is a long-acting synthetic GLP‑1 single-target lyophilized peptide solely for laboratory research use. Each sealed sterile single vial contains 20 mg pure sg freeze-dried white powder, hence the product code SM20. HPLC testing confirms its purity exceeds 99.5%, free of heavy metals, pyrogens and irrelevant excipients, fully meeting research-grade peptide raw material standardshomopeptid....
As a selective GLP‑1 receptor agonist modified with fatty acid side chains, SM20 binds albumin to extend its biological half-life, distinguishing it from dual-pathway metabolic peptides such as TT. Before subcutaneous injection for experimental trials, SM20 dry powder must be fully reconstituted with bacteriostatic water. Undissolved lyophilized powder requires light-proof, airtight storage at -20°C for long-term stability; diluted peptide solution retains complete biological activity for a maximum of 21 days under refrigeration (2–8°C). This product has not obtained global regulatory approval for human clinical treatment, injection or oral administration, and is restricted exclusively to in-vitro GLP‑1 receptor research and animal metabolic disorder modeling experiments.
SM20 activates GLP‑1 single pathway to trigger glucose-dependent insulin secretion from pancreatic beta cells and suppress excessive hepatic glucagon output. It effectively lowers fasting blood glucose and smooths postprandial blood sugar surges, steadily reducing glycated hemoglobin levels in type 2 diabetes research models. Its glucose-dependent activation mechanism minimizes hypoglycemia risk, and long-term intervention relieves chronic peripheral insulin resistance in metabolic injury subjects.
By delaying gastric emptying and activating central satiety signals, SM20 naturally cuts daily calorie intake. It accelerates lipolysis of white adipose tissue, preferentially eliminating harmful visceral fat while preserving lean muscle mass. Research data proves SM20 delivers steady total weight loss effects, efficiently lowering BMI and body fat ratio in obese animal models without excessive muscle loss.
SM20 crosses the blood-brain barrier to act on the hypothalamic satiety center, extending post-meal fullness duration and suppressing strong cravings for high-sugar, high-fat calorie-dense foods. It normalizes irregular eating frequency and reduces uncontrolled overeating impulses, supporting sustainable weight management without extreme calorie restriction in research protocols.
SM20 optimizes systemic lipid profiles by lowering triglycerides and low-density lipoprotein cholesterol. It relieves obesity-induced hypertension and mild obstructive sleep apnea, mitigates chronic low-grade systemic inflammation, and delivers auxiliary regulatory effects on non-alcoholic fatty liver lesions. It also provides mild protective benefits for cardiovascular endothelial function by reducing circulating metabolic inflammatory markers.
SM20, short for sg 20mg, is a long-acting synthetic GLP‑1 single-target lyophilized peptide solely for laboratory research use. Each sealed sterile single vial contains 20 mg pure sg freeze-dried white powder, hence the product code SM20. HPLC testing confirms its purity exceeds 99.5%, free of heavy metals, pyrogens and irrelevant excipients, fully meeting research-grade peptide raw material standardshomopeptid....
As a selective GLP‑1 receptor agonist modified with fatty acid side chains, SM20 binds albumin to extend its biological half-life, distinguishing it from dual-pathway metabolic peptides such as TT. Before subcutaneous injection for experimental trials, SM20 dry powder must be fully reconstituted with bacteriostatic water. Undissolved lyophilized powder requires light-proof, airtight storage at -20°C for long-term stability; diluted peptide solution retains complete biological activity for a maximum of 21 days under refrigeration (2–8°C). This product has not obtained global regulatory approval for human clinical treatment, injection or oral administration, and is restricted exclusively to in-vitro GLP‑1 receptor research and animal metabolic disorder modeling experiments.
SM20 activates GLP‑1 single pathway to trigger glucose-dependent insulin secretion from pancreatic beta cells and suppress excessive hepatic glucagon output. It effectively lowers fasting blood glucose and smooths postprandial blood sugar surges, steadily reducing glycated hemoglobin levels in type 2 diabetes research models. Its glucose-dependent activation mechanism minimizes hypoglycemia risk, and long-term intervention relieves chronic peripheral insulin resistance in metabolic injury subjects.
By delaying gastric emptying and activating central satiety signals, SM20 naturally cuts daily calorie intake. It accelerates lipolysis of white adipose tissue, preferentially eliminating harmful visceral fat while preserving lean muscle mass. Research data proves SM20 delivers steady total weight loss effects, efficiently lowering BMI and body fat ratio in obese animal models without excessive muscle loss.
SM20 crosses the blood-brain barrier to act on the hypothalamic satiety center, extending post-meal fullness duration and suppressing strong cravings for high-sugar, high-fat calorie-dense foods. It normalizes irregular eating frequency and reduces uncontrolled overeating impulses, supporting sustainable weight management without extreme calorie restriction in research protocols.
SM20 optimizes systemic lipid profiles by lowering triglycerides and low-density lipoprotein cholesterol. It relieves obesity-induced hypertension and mild obstructive sleep apnea, mitigates chronic low-grade systemic inflammation, and delivers auxiliary regulatory effects on non-alcoholic fatty liver lesions. It also provides mild protective benefits for cardiovascular endothelial function by reducing circulating metabolic inflammatory markers.
,Manufacturer ,Online Seller ,Importer 